Quantitative analysis of insulin-like growth factor 2 receptor and insulin-like growth factor binding proteins to identify control mechanisms for insulin-like growth factor 1 receptor phosphorylation

BackgroundThe insulin-like growth factor (IGF) system impacts cellular development by regulating proliferation, differentiation, and apoptosis, and is an attractive therapeutic target in cancer. The IGF system is complex, with two ligands (IGF1, IGF2), two receptors (IGF1R, IGF2R), and at least six high affinity IGF-binding proteins (IGFBPs) that regulate IGF ligand bioavailability. While the individual components of the IGF system are well studied, the question of how these different components integrate as a system to regulate cell behavior is less clear.ResultsTo analyze the relative importance of different mechanisms that control IGF network activity, we developed a mass-action kinetic model incorporating cell surface binding, phosphorylation, and intracellular trafficking events. The model was calibrated and validated using experimental data collected from OVCAR5, an immortalized ovarian cancer cell line. We then performed model analysis to examine the ability of IGF2R or IGFBPs to counteract phosphorylation of IGF1R, a critical step for IGF network activation. This analysis suggested that IGF2R levels would need to be 320-fold greater than IGF1R in order to decrease pIGF1R by 25 %, while IGFBP levels would need to be 390-fold greater. Analysis of The Cancer Genome Atlas (TCGA) data set suggested that this level of overexpression is unlikely for IGF2R in ovarian, breast, and colon cancer. In contrast, IGFBPs can likely reach these levels, suggesting that IGFBPs are the more critical regulator of IGF1R network activity. Levels of phosphorylated IGF1R were insensitive to changes in parameters regulating the IGF2R arm of the network.ConclusionsUsing a mass-action kinetic model, we determined that IGF2R plays a minor role in regulating the activity of IGF1R under a variety of conditions and that due to their high expression levels, IGFBPs are the dominant mechanism to regulating IGF network activation.

[1]  W. Meyers,et al.  Transforming Growth Factor‐Beta Receptors and Mannose 6‐Phosphate/Insulin‐Like Growth Factor‐II Receptor Expression in Human Hepatocellular Carcinoma , 1995, Annals of surgery.

[2]  M. Pacher,et al.  Insulin-Like Growth Factor (IGF)-I and IGF-II Serum Concentrations in Patients with Benign and Malignant Breast Lesions , 2004, Clinical Cancer Research.

[3]  David W. Smith,et al.  Modeling the Insulin-Like Growth Factor System in Articular Cartilage , 2013, PloS one.

[4]  A. Efstratiadis,et al.  A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting , 1990, Nature.

[5]  S. Kornfeld.  Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. , 1992, Annual review of biochemistry.

[6]  R. Lucito,et al.  Protein-tyrosine Phosphatase 1B Antagonized Signaling by Insulin-like Growth Factor-1 Receptor and Kinase BRK/PTK6 in Ovarian Cancer Cells*♦ , 2013, The Journal of Biological Chemistry.

[7]  B. Fisch,et al.  Pilot study of isolated early human follicles cultured in collagen gels for 24 hours. , 1999, Human reproduction.

[8]  L. Giudice,et al.  Insulin-like growth factor-binding proteins in the human fetus: tissue-specific protein secretion, immunologic characterization, and gene expression. , 1994, American journal of obstetrics and gynecology.

[9]  X. Lu,et al.  Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with significant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: role of IGF-II. , 1996, Endocrinology.

[10]  M. Washington,et al.  M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity , 1995, Nature Genetics.

[11]  H. Werner,et al.  Targeting IGF-1 signaling pathways in gynecologic malignancies , 2013, Expert opinion on therapeutic targets.

[12]  J. Chang-Claude,et al.  Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). , 2007, Endocrine-related cancer.

[13]  A. Berchuck,et al.  High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. , 2005, Gynecologic oncology.

[14]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[15]  R. Huber,et al.  Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins , 2006, Proceedings of the National Academy of Sciences.

[16]  Zhihong Chen,et al.  Decreased expression of the mannose 6- phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells , 2002, BMC Cancer.

[17]  L. Powell-Braxton,et al.  Inactivation of the IGF‐I Gene in Mice Results in Perinatal Lethality , 1993, Annals of the New York Academy of Sciences.

[18]  Jason S. Lee,et al.  Increased expression of the mannose 6‐phosphate/insulin‐like growth factor‐II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo , 2003, International journal of cancer.

[19]  Jing Wang,et al.  Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance , 2014, Genes & diseases.

[20]  Dan Tian,et al.  Analysis of cancer signaling networks by systems biology to develop therapies. , 2011, Seminars in cancer biology.

[21]  Melanie I. Stefan,et al.  Molecules for memory: modelling CaMKII , 2007, BMC Systems Biology.

[22]  L. Giudice,et al.  Gestational age-dependent expression of insulin-like growth factor-binding protein-1 (IGFBP-1) phosphoisoforms in human extraembryonic cavities, maternal serum, and decidua suggests decidua as the primary source of IGFBP-1 in these fluids during early pregnancy. , 1997, The Journal of clinical endocrinology and metabolism.

[23]  P. Rumsby.  Vital factors in liver cancer , 1996, Human & experimental toxicology.

[24]  Andrew W Roddam,et al.  Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies , 2010, The Lancet. Oncology.

[25]  M. Czech,et al.  Direct demonstration of rapid insulin-like growth factor II Receptor internalization and recycling in rat adipocytes. Insulin stimulates 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process. , 1985, The Journal of biological chemistry.

[26]  M. Pollak.  The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[27]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[28]  Daling Zhu,et al.  Local Expression of Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-I Receptor, and Estrogen Receptor Alpha in Ovarian Cancer , 2009, Oncology Research and Treatment.

[29]  J. Byrd,et al.  Mechanisms for High Affinity Mannose 6-Phosphate Ligand Binding to the Insulin-like Growth Factor II/Mannose 6-Phosphate Receptor , 2000, The Journal of Biological Chemistry.

[30]  P. D'Amore,et al.  IGF2: epigenetic regulation and role in development and disease. , 2008, Cytokine & growth factor reviews.

[31]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[32]  Sandra,et al.  A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. , 1998, Cancer research.

[33]  T. Wood,et al.  Insulin-like Growth Factor Type-I Receptor Internalization and Recycling Mediate the Sustained Phosphorylation of Akt* , 2007, Journal of Biological Chemistry.

[34]  Dan Tian,et al.  Analysis of the quantitative balance between insulin-like growth factor (IGF)-1 ligand, receptor, and binding protein levels to predict cell sensitivity and therapeutic efficacy , 2014, BMC Systems Biology.

[35]  Jun Li,et al.  TCPA: a resource for cancer functional proteomics data , 2013, Nature Methods.

[36]  S. Ramaswamy,et al.  A Molecular Roadmap of Reprogramming Somatic Cells into iPS Cells , 2012, Cell.

[37]  J. Baker,et al.  Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) , 1993, Cell.

[38]  G. Loughran,et al.  Identification of an IGF-1R kinase regulatory phosphatase using the fission yeast Schizosaccharomyces pombe and a GFP tagged IGF-1R in mammalian cells , 2002, Molecular pathology : MP.

[39]  R. Drapkin,et al.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research. , 2016, Cancer research.

[40]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[41]  J. Minna,et al.  A systematic analysis reveals heterogeneous changes in the endocytic activities of cancer cells. , 2015, Cancer research.

[42]  D. Katsaros,et al.  IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. , 2001, European journal of cancer.

[43]  J. Toretsky,et al.  Involvement of IGF-II in human cancer. , 1996, The Journal of endocrinology.

[44]  D. Katsaros,et al.  IGF-I in epithelial ovarian cancer and its role in disease progression , 2007, Growth factors.

[45]  P. Torng,et al.  Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma , 2008, Oncogene.

[46]  S. Plymate,et al.  Insulin‐like growth factor binding protein‐3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo , 2002, The Prostate.

[47]  R. Baxter,et al.  IGF binding proteins in cancer: mechanistic and clinical insights , 2014, Nature Reviews Cancer.

[48]  W. Sly,et al.  The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells. , 1988, Journal of Biological Chemistry.

[49]  T. Chard.  Insulin-like growth factors and their binding proteins in normal and abnormal human fetal growth. , 1994, Growth regulation.

[50]  J. Frystyk,et al.  Elevated free IGF2 levels in localized, early-stage breast cancer in women. , 2008, European journal of endocrinology.

[51]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[52]  E. Wagner,et al.  Regulation of embryonic growth and lysosomal targeting by the imprintedIgf2/Mpr gene , 1994, Nature.

[53]  Ziying Liu,et al.  Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. , 1994, Genes & development.

[54]  A. Ullrich,et al.  Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. , 1990, The Biochemical journal.

[55]  H. Arnqvist,et al.  Human aortic smooth muscle cells are insulin resistant at the receptor level but sensitive to IGF1 and IGF2. , 2009, Journal of molecular endocrinology.